Granules added that manufacturing and distribution of its existing products at the facility will continue unaffected.

Granules India's shares fell nearly 8% after the US FDA issued a warning letter regarding its Gagillapur facility, citing ...

"On February 26, 2025, the US FDA issued a Warning Letter to Granules' Gagillapur facility based on its inspection conducted ...

The Warning Letter is dated February 26, 2025 and the facility continues to hold an "Official Action Indicated" (OAI) status.

The USFDA issued a warning letter to Granules India Ltd's Gagillapur facility after an August 2024 inspection highlighted ...

Granules India's Gagillapur facility receives FDA warning letter, impacting product submissions review until resolved, company remains confident in resolution.

The development may temporarily delay the approval of pending product submissions from the site, but existing manufacturing ...

Drug firm Granules India Ltd on Thursday (February 27) announced that the US FDA has issued a Warning Letter for its ...

Seeing the words "Class I food recall" might make you think of contaminated products sitting on grocery store shelves, but ...

USFDA issues warning letter to Jagsonpal Pharmaceuticals for manufacturing lapses at Rajasthan plant, demands corrective ...

The USFDA has issued a warning letter to Jagsonpal Pharmaceuticals for significant manufacturing lapses at its ...